Key Highlights
- Generateand Novartis announce multi-target collaboration to develop protein therapeutics.
- Generative AI to enhance drug discovery using “The Generate Platform.”
- Generate to receive $65 million upfront and over $1 billion in potential milestone payments.
- Collaboration accelerates next-gen biologics development in various disease areas.
Source: Business Wire
Notable Quotes
- “This collaboration offers an opportunity to leverage the unique strengths of our respective companies…to bring forward new medicines with transformative potential for patients.” — Fiona Marshall, President of Biomedical Research at Novartis
- “Partnering with Novartis allows us to broaden the use of our cutting-edge generative biology platform to tackle even more areas of unmet medical need.” — Mike Nally, CEO at Generate
SoHC's Take
This collaboration between Generate and Novartis represents a significant leap in the application of AI for drug discovery, particularly in the emerging field of generative biology. By combining the AI-driven capabilities of Generate’s platform with Novartis’ deep expertise in biologics development, the partnership is poised to accelerate the creation of first-in-class and best-in-class protein-based therapeutics. The deal not only provides a strong financial upside for Generate but also signals a broader shift in the pharmaceutical industry towards integrating advanced AI technologies to overcome previously undruggable targets, offering hope for faster, more effective treatments in multiple therapeutic areas.
